Nanopublication: RAJ-Fulmtf

Full identifier: http://purl.org/np/RAJ-FulmtfSIh2pEjbZh2Q2wd1-17aBh1AWVr1IBwbktU

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RAJ-Fulmtf comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAJ-Fulmtf...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "imbruvica is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy 1 1 chronic lymphocytic leukemia cll small lymphocytic lymphoma sll 1 2 chronic lymphocytic leukemia cll small lymphocytic lymphoma sll with 17p deletion 1 3 waldenstrom s macroglobulinemia wm 1 4 marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anti cd2 based therapy 1 5 chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy 1 6 imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma mcl who have received at least one prior therapy accelerated approval was granted for this indication based on overall response rate continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial see clinical studies 14 1 imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll small lymphocytic lymphoma sll imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll small lymphocytic lymphoma sll with 17p deletion imbruvica is indicated for the treatment of adult patients with waldenstrom s macroglobulinemia wm imbruvica is indicated for the treatment of adult patients with marginal zone lymphoma mzl who require systemic therapy and have received at least one prior anti cd2 based therapy accelerated approval was granted for this indication based on overall response rate see clinical studies 14 4 imbruvica is indicated for the treatment of adult patients with chronic graft versus host disease cgvhd after failure of one or more lines of systemic therapy" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAJ-Fulmtf... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T14:53:47.666+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAJ-Fulmtf... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAJ-Fulmtf... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAJ-Fulmtf... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAJ-Fulmtf...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAJ-Fulmtf... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAJ-Fulmtf...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 3 Jul 2021, 12:53:47 UTC

show references